sterna biologicals home


Christian Pangratz
CEO and
Managing Director

Christian Pangratz

Before joining sterna, Christian was Senior Vice President of Business Development at Vectura Group plc. He also served as Non-Executive Director on the Board of Directors of Skyepharma AG and Jagotec AG, both subsidiaries of Vectura in Switzerland, and on the Board of Directors of Tianjin Kinnovata Pharmaceutical Co. Ltd., a China-based joint venture between Vectura and Tianjin KingYork Group Company Ltd.

From 2014 to 2016, Christian was Executive Vice President of Business Development, Alliance Management & Project Management at Skyepharma in Basel, Switzerland. Prior to this, he served as Chief Business Officer at Activaero, a German-American respiratory company, where he helped to grow the marketing and business development functions and played an instrumental role in the Company’s trade sale to Vectura in 2014.

From 2004 to 2011, Christian held a number of senior marketing, new product planning, project management, business development and alliance management positions at Nektar Therapeutics in San Francisco. Before moving to the United States, he gained extensive sales and marketing experience at Bayer and Pfizer across various European markets.

Christian also was an Adjunct Professor at Webster University in Vienna, Austria, where he taught a Marketing Strategy & Execution class. He earned both a bachelor’s degree in Business Administration and a master’s degree in International Business from Webster University.


Jonas Renz
Managing Director


Jonas joined sterna biologicals in 2011 and is a Managing Director of the company.

Prior to joining sterna biologicals, he held various positions with investment management firms.

After graduating from Oxford University, Jonas joined Goldman Sachs’ Principal Investment Area in London, where he worked on a number of private equity transactions for the Goldman Sachs Capital Partners family of funds. In 2006, he moved to Och-Ziff Capital Management in London, where his responsibilities included special situations and equity long/short investments. In 2009, he founded an investment management company in Berlin.


Ursula Homburg  
Head of Research & Deveopment


Ursula joined sterna biologicals in 2011 to lead the company’s R&D activities.

She has considerable experience in immunology, oncology, drug development, and regulatory affairs. Her previous professional career includes heading the newly-founded Centre of Oncology in Kassel and working on the development of therapeutic antibodies with U3 Pharma AG in Martinsried.

Ursula received her diploma in molecular medicine from the University of Erlangen-Nürnberg and wrote her diploma thesis at the UniSpital Zurich (Division of Immunology).

© sterna biologicals GmbH & Co. KG • Bismarckstraße 7 • D-35037 Marburg